Search
tucatinib; irbinitinib (Tukysa)
Indications:
- HER2+ breast cancer with brain metastases
* indicated in combination with trastuzumab & capecitabin [2]
Dosage:
- 300 mg PO BID with or without food
Tablets: 50 & 150 mg
Pharmacokinetics:
- crosses blood brain barrier
Adverse effects:
> 20%
- diarrhea
- palmar-plantar erythrodysesthesia
- nausea/vomiting
- fatigue
- hepatotoxicity
- stomatitis
- abdominal pain
- headache
- anemia
- rash
Mechanism of action:
- oral tyrosine kinase inhibitor, targets only HER2
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=1039094
References
- MedPage Today Staff. Feb 3, 2020
HER2 Breast Cancer Treatment Effective on Brain Metastases -
Patients with brain metastases have historically been excluded from
most clinical trials.
https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/84671
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Tukysa* (tucatinib) tablets, for oral use
https://seagendocs.com/TUKYSA_Full_Ltr_Master.pdf
- Medscape: tucatinib (Rx)
https://reference.medscape.com/drug/tukysa-tucatinib-4000071